Monograph
V08CA10 - Gadoxetic Acid |
Propably not porphyrinogenic |
PNP |
Rationale
Gadoxetic disodium is not metabolized by CYP enzymes.
Therapeutic characteristics
Gadoxetic acid is indicated for the detection of focal liver lesions and provides information on the character of lesions in T1-wighted magnetic resonance imaging (MRI). It is for diagnostic use by intravenous administration only.
Common side effects are nausea and headache.
Metabolism and pharmacokinetics
Gadoxetate disodium is not metabolized. It is excreted in the urine and feces. Elimination half-life is 1 hour.
It is highly water-soluble and less than 10% is bound to proteins in vivo.
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Primovist.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Iceland
Finland
Latvia
Serbia© NAPOS 2024